Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Common Cold Clinical Trial

Official title:

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold: a Prospective, Randomized, Double-blind, Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05070650
• Other study ID #: SAN-0657
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 20, 2024
• Est. completion date: April 30, 2025

Study information

• Verified date: August 2023
• Source: Sandoz
• Contact: Sandoz
• Phone: +49 8024 908 0
• Email: sandoz.disclosure[@]sandoz.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, randomized, multinational, multicenter, double-blind trial in 2 parallel groups of patients

Description:

This study is a prospective, randomized, multinational, multicenter, double-blind trial in 2 parallel groups of patients.

Patients will undergo screening examinations at Visit 1.

Patients who meet all of the inclusion and none of the exclusion criteria will be randomized to double-blind treatment with one of the following:

• Group A: Acetylcysteine/Paracetamol/Phenylephrine: one sachet three times per day OR

• Group B: Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day.

A control visit (Visit 2) is planned on Day 3 of treatment.

After the end of the double-blind treatment phase, the patients will undergo an end-of-treatment (EOT) examination at Visit 3 on Day 6.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1002
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects aged between 18 and 75 years inclusive on the date of consent

2. No fever or (mild) fever below 38.5° C

3. Total score (sum of all ratings) of 2 or higher based on the rating of the following symptoms of common cold (Jackson scale):

1. Sneezing

2. Nasal discharge

3. Nasal obstruction

4. Sore throat

5. Cough

6. Headache

7. Malaise

8. Chilliness according to the following rating scale: 0 = absent, 1 = mild, 2 = moderate, or 3 = severe

4. Presence of cough with thick mucus production

5. Informed consent to participate in the trial provided in written form

Exclusion Criteria:

1. Duration of any of the symptoms of common cold of more than 72 hours at the time of screening

2. History of hypersensitivity or intolerance to the active substances or any of the excipients of the trial medication

3. Known bronchial asthma or chronic obstructive pulmonary disease

4. Known duodenal or gastric ulcer

5. Known hyperthyroidism

6. Known narrow angle glaucoma

7. Known pheochromocytoma

8. Known prostate adenoma with urine retention

9. Known severe liver failure (Child-Pugh > 9)

10. Known severe cardio-vascular diseases

11. Known porphyria

12. Known glucose-6-phosphate dehydrogenase deficiency

13. High fever (body temperature above 38.5°C)

14. Intake of antibiotics, immunosuppressing, immuno-stimulating or immuno-modulating medication, within 30 days prior to screening visit

15. Intranasal or systemic use of corticosteroids within 30 days prior to screening visit

16. Intake of antihistamines or nasal decongestants within 48 hours prior to screening visit

17. Vaccination within 14 days prior to screening visit

18. Immunocompromised state

19. Suspicion for acute bacterial infection

20. Pregnant or breast-feeding female patient

21. Female patient of childbearing potential (not surgically sterilized/ hysterectomized or postmenopausal for at least 1 year) who is not currently using (documented at screening visit) and not willing to use medically reliable methods of contraception for the entire trial duration such as barrier method, oral, injectable or implantable contraceptives, intrauterine contraceptive devices (IUD), sexual abstinence or vasectomized partner

22. Any other condition of the patient (e.g. serious or unstable medical or psychological condition, acute psychosis) that in the opinion of the investigator may compromise evaluation of the trial treatment or may jeopardize patient's safety, compliance or adherence to protocol requirements

23. Participation in ANY research study involving another investigational medicinal product (IMP) within 30 days prior to screening visit, or simultaneous participation in another clinical study or previous participation in present study

24. Suspected alcohol/ drug dependence or abuse (including heavy smoking: = 20 cigarettes daily)

25. Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial

26. Subjects who are known or suspected:

• not to comply with the trial directives

• not to be reliable or trustworthy

• to be a dependent person, e.g. a relative, family member, or member/ employee of the investigator's or sponsor's staff

• subject is in custody or submitted to an institution due to a judicial order.

Related Conditions & MeSH terms

• Common Cold

Intervention

Drug:
• Acetylcysteine
200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
• Paracetamol
500 mg/10 mg granules for oral solution: one sachet three times per day
• Phenylephrine
500 mg/10 mg granules for oral solution

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sandoz

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the daily Score of 8 symptoms related to mucus production (SUM8)	Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.	Baseline, Day 5
Secondary	Number of adverse events and serious adverse events	Assessment of safety and tolerability of the investigational medicinal product against the comparator product for the treatment of common cold	Until Day 6, or earlier in case of premature termination
Secondary	Time to onset of action	Time to onset of action defined as first day of treatment with investigational product on which SUM8 shows statistically significant difference from the comparator product will be reported	Day 1 to Day 5
Secondary	Score of 8 symptoms related to mucus production (SUM8) development over the course of the study	Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.	Baseline, Day 1 to Day 5
Secondary	Assessment of separate items of Score of 8 symptoms related to mucus production (SUM8)	Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.	Baseline, Day 1 to Day 5
Secondary	Sum of changes from baseline in the daily Wisconsin Upper Respiratory Symptom Survey (WURSS-21)	The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.	Baseline, Day 1 to Day 5
Secondary	Assessment of separate items of Wisconsin Upper Respiratory Symptom Survey (WURSS-21)	The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.	Baseline, Day 1 to Day 5
Secondary	Percentage of responders and non-responders to treatment	Percentage of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator will be reported.	On Day 3, and after the end of treatment on Day 6